Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hengliflozin + metformin vs metformin in type 2 diabetes mellitus with hyperuricemia
ChiCTR2500109541Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guilin Medical University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin and metformin in type 2 diabetes mellitus (T2DM) and hyperuricemia (2 arms), sponsored by The First Affiliated Hospital of Guilin Medical University. Primary endpoints: HbA1c at 24 weeks and serum uric acid. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
empagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)hyperuricemia
Beyond the preview
Go deeper on ChiCTR2500109541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109541.